Marian Ali J
Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, University of Texas Health Sciences Center at Houston, Houston, Texas.
JACC Basic Transl Sci. 2020 Oct 26;5(10):1029-1042. doi: 10.1016/j.jacbts.2020.05.013. eCollection 2020 Oct.
Genetic variants are major determinants of susceptibility to disease, response to therapy, and clinical outcomes. Advances in the short-read sequencing technologies, despite some shortcomings, have enabled identification of the vast majority of the genetic variants in each genome. The major challenge is in identifying the pathogenic variants in cardiovascular diseases. The yield of the genetic testing has been limited because of technological shortcomings and our incomplete understanding of the genetic basis of cardiovascular disorders. To advance the field, a shift to long-read sequencing platforms is necessary. In addition, to discern the pathogenic variants, genetic diseases should be considered as a continuum and the genetic variants as probabilistic factors with a gradient of effect sizes. Moreover, disease-specific physician-scientists with expertise in the clinical medicine and molecular genetics are best equipped to discern functional and clinical significance of the genetic variants. The changes would be expected to enhance clinical utilities of the genetic discoveries.
基因变异是疾病易感性、对治疗的反应以及临床结果的主要决定因素。尽管存在一些缺点,但短读长测序技术的进步已使人们能够识别每个基因组中的绝大多数基因变异。主要挑战在于识别心血管疾病中的致病变异。由于技术缺陷以及我们对心血管疾病遗传基础的不完全理解,基因检测的成效一直有限。为推动该领域发展,有必要转向长读长测序平台。此外,为了辨别致病变异,应将遗传疾病视为一个连续体,并将基因变异视为具有效应大小梯度的概率因素。而且,具备临床医学和分子遗传学专业知识的特定疾病领域的医师科学家最有能力辨别基因变异的功能和临床意义。预计这些改变将提高基因发现的临床效用。